Is Guardant Health Stock a Buy?
Many cancer patients undergoing treatment have impaired immune systems, so it's not a big surprise that some of them stayed away from clinic settings during the spring, when cases of COVID-19 were growing rapidly in the United States. Guardant Health (NASDAQ: GH), a company specializing in detecting cancer DNA circulating in the blood, saw a dip in clinical volume during that time, dampening results after the company more than doubled its revenue last year. Guardant's revenue comes from tests taken by seriously ill cancer patients and drug companies conducting research in new treatments, and neither of those sorts of customers are going to put off buying the company's products for long.
